<DOC>
	<DOC>NCT01832558</DOC>
	<brief_summary>In a prospective single centre placebo-controlled trial over ten weeks, 24 CKD II-III patients (eGFR 30-89 ml/min per 1.73 m2) with DM II will be randomized to enalapril 20mg per day after a two week run-in phase. Thereafter, patients will either receive eplerenone 25mg (n=12) or a placebo (n=12) for eight weeks. Eplerenone will be increased to 50mg under close monitoring of serum potassium levels. Employing a novel mass-spectrometry ( MS)-based method, quantification of up to 10 different Ang metabolites (Ang I, Ang II, Ang 1-7, Ang 1-9, Ang 2-10, Ang 1-5, Ang 2-7, Ang 3-7, Ang 3-8 and Ang 2-8) will be performed simultaneously out of blood sera (after run-in phase and after 10 weeks).</brief_summary>
	<brief_title>The EPOCH Study (Eplerenone on Top of ACE Inhibition in Chronic Kidney Disease Patients With Hypertension)</brief_title>
	<detailed_description />
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>CKD II to III and diabetes mellitus type 2 CKD will be defined according to estimated glomerular filtration rate (eGFR) with the MDRD formula eGFR between 30 and 89 ml/min albumin excretion rates &gt; 300 mg/24 hours (UACR &gt; 300 mg/gram) or &gt; 200 mg/g if already receiving any RAS blockade Patients should be hypertonic stage I or II according to the European guidelines (Chobanian et al. JAMA 2003) Age &lt; 18 years UACR &gt; 3500mg/g severe hypertension pregnancy unwilling or inability to sign the informed consent coronary heart disease systolic blood pressure &lt; 130 mmHg additional RAS interfering drugs (ACEis, ARBs, direct renin inhibitors) 25hydroxy vitamin D levels below 16.6±8.3 pg/ml 1,25dihydroxy vitamin D 33.1±15.5 pg/ml Intolerance to eplerenon or an excipient of it: tablettcore: LactoseMonohydrat Mikrokristalline Cellulose (E 460) Croscarmellosesodium (E 468) Hypromellose (E 464) Sodiumdodecylsulfat Talkum (E 553b) Magnesiumstearat (E 470b) filmcoat Opadry, yellow: Hypromellose (E 464) Titandioxid (E 171) Macrogol 400 Polysorbat 80 (E 433) Yellow ironoxide (E 172) Red ironoxide (E 172) Patients with Serumpotassium &gt; 5,0 mmol/l at start of the treatment Patients with severe renal insufficiency (eGFR &lt;30ml/min./1.73 m2) Patients with severe liver insufficiency (ChildPugh class C) Patients taking potassium saving diuretics, potassium supplements or strong CYP3A4inhibitors (z. B. Itraconazol, Ketoconazol, Ritonavir, Nelfinavir, Clarithromycin, Telithromycin und Nefazodon)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>